Choles-Restore ACC™

Choles-Restore ACC™

Maintains Good Health

60 Tablets ( SKU: 9320, NPN: 80051618 )

Benefits

  • Provides niacin (nicotinic acid) as intermediate release form; extensively documented improvement in dyslipidemia and inflammation
  • High potency dosing, with 475 mg nicotinic acid, 75 mg Sytrinol, and 62.5 mg Hibiscus sabdariffa per tablet, all clinically relevant dosages
  • Well-suited for patients with mixed dyslipidemias, considering multiple lipid modifying and anti-inflammatory effects of diverse anti-atherogenic ingredients
  • Suitable for vegetarians/vegans

Feature Summary

A unique combination of cholesterol lowering agents, Choles-Restore AAC targets atherogenic lipids as well as endothelial health, with ingredients proven to lower the risk of cardiovascular events. Niacin is a pleotropic molecule, reducing levels of all atherogenic particles containing apoB, including LDL-C, triglycerides, and Lp(a).1 Although niacin is the only known substance to significantly increase HDL cholesterol, a large body of clinical evidence has found it significantly reduces both cardiovascular events and major coronary heart disease, potentially through unrelated mechanisms.2 It improves endothelial function, and reduces carotid intima-media thickness and C-reactive protein among participants with the metabolic syndrome.3,4 The intermediate release form is the treatment of choice, as it is associated both with lower hepatic toxicity as well as reduced flushing.

Choles-Restore AAC also contains Sytrinol, a unique combination of citrus flavonoids and palm tocotrienols shown to inhibit apoB synthesis, as well as apoB containing lipids.5 Citrus flavonoids also blunt inflammation in key metabolic tissues, and normalize insulin sensitivity.6 Lastly, Hibiscus sabdariffa has anti-hyperlipidemic effects, reduces LDL peroxidation, and stimulates cholesterol removal from macrophages by a unique mechanism,7,8 completing this synergistic anti-atherogenic blend.

Medicinal Ingredients

Serving Size: 1 Tablet
Servings per Container: 60

Each Tablet Contains:
Niacin (Nicotinic Acid).................................................. 475 mg
Sytrinol®......................................................................... 75 mg
Orange Extract (Citrus aurantium/Citrus nobilis) (peel)
(24.3 mg Polymethoxylated Flavones)...........................67.5 mg
Palm Extract (Elaeis guineensis) (seed oil) (1.125 mg Tocotrienols)............ 7.5 mg
Roselle 4:1 Extract (Hibiscus sabdariffa) (flower)..........................62.5 mg
(Standardized to contain 6% Anthocyanins)

Non-Medicinal Ingredients

Dibasic calcium phosphate dihydrate, carbohydrate gum [cellulose], microcrystalline cellulose, coating (carbohydrate gum [cellulose], glycerin), vegetable grade magnesium stearate (lubricant).

Allergens:

Contains no artificial colours, preservatives, or sweeteners; no dairy, starch, sugar, wheat, gluten, yeast, soy, egg, fish, shellfish, animal products, salt, tree nuts, or GMOs. Suitable for vegetarians/vegans. Sealed for your protection. Do not use if seal is broken. For freshness, store in a cool, dry place.

Contraindications

Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Do not exceed the recommended dose except on the advice of a health care practitioner. People sensitive to nicotinic acid may experience flushing of the skin that is generally mild and transient. Keep out of reach of children.

Drug Interactions

Favourable effects have been well-documented when used in conjunction with statin drugs for dyslipidemia, and may allow for reduced dosing of statins.9 Antioxidant supplementation (vitamins E and C, beta-carotene, and selenium) may blunt the favourable effect of niacin on HDL levels. Evidence exists for a synergistic effect on glycemic control when used with chromium.10

  1. Creider JC, Hegele RA, Joy TR. Niacin: another look at an underutilized lipid-lowering medication. Nat Rev Endocrinol. 2012 Sep;8(9):517-28. doi: 10.1038/nrendo.2012.22.
  2. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013 Jan 29;61(4):440-6. doi: 10.1016/j.jacc.2012.10.030.
  3. Sahebkar A. Effect of niacin on endothelial function: A systematic review and meta-analysis of randomized controlled trials. Vasc Med. 2014 Jan 3. [Epub ahead of print]
  4. Thoenes, M. et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int. J. Clin. Pract. 61, 1942–1948 (2007).
  5. Roza JM, Xian-Liu Z, Guthrie N. Effect of citrus flavonoids and tocotrienols on serum cholesterol levels in hypercholesterolemic subjects. Altern Ther Health Med. 2007 Nov-Dec;13(6):44-8.
  6. Assini JM, Mulvihill EE, Huff MW. Citrus flavonoids and lipid metabolism. Curr Opin Lipidol. 2013 Feb;24(1):34-40. doi: 10.1097/MOL.0b013e32835c07fd.
  7. Chen JH, Wang CJ, Wang CP, Sheu JY, et al. Hibiscus sabdariffa leaf polyphenolic extract inhibits LDL oxidation and foam cell formation involving up-regulation of LXRα/ABCA1 pathway. Food Chem. 2013 Nov 1;141(1):397-406. doi: 10.1016/j.foodchem.2013.03.026.
  8. Hopkins AL, Lamm MG, Funk JL, Ritenbaugh C. Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies. Fitoterapia. 2013 Mar;85:84-94. doi: 10.1016/j. fitote.2013.01.003.
  9. Toth PP, Thakker KM, Jiang P, et al. Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. Vasc Health Risk Manag. 2012;8:39-44.
  10. Urberg M, Zemel MB. Evidence for synergism between chromium and nicotinic acid in the control of glucose tolerance in elderly humans. Metabolism 1987;36:896-9.